Header Logo

Connection

JORGE E CORTES to Janus Kinase 2

Back to Details
This is a "connection" page, showing publications JORGE E CORTES has written about Janus Kinase 2.
JORGE E CORTES
Connection Strength
1.251
Janus Kinase 2
  1. A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. Leuk Res. 2015 Feb; 39(2):157-63.
    View in: PubMed
    Score: 0.086
  2. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):171-6.
    View in: PubMed
    Score: 0.085
  3. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar; 38(3):316-22.
    View in: PubMed
    Score: 0.081
  4. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood. 2013 Nov 28; 122(23):3784-6.
    View in: PubMed
    Score: 0.079
  5. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a. Blood. 2013 Aug 08; 122(6):893-901.
    View in: PubMed
    Score: 0.078
  6. Molecular targeted therapy in acute myeloid leukemia. Hematology. 2012 Apr; 17 Suppl 1:S59-62.
    View in: PubMed
    Score: 0.072
  7. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. 2011 Nov 01; 117(21):4869-4877.
    View in: PubMed
    Score: 0.067
  8. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011 Mar 01; 29(7):789-96.
    View in: PubMed
    Score: 0.066
  9. Competing cell clones in myeloproliferative neoplasm. Blood. 2010 Dec 02; 116(23):5074-5.
    View in: PubMed
    Score: 0.065
  10. Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer. 2011 Feb 15; 117(4):662-76.
    View in: PubMed
    Score: 0.065
  11. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16; 363(12):1117-27.
    View in: PubMed
    Score: 0.064
  12. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010 Feb 11; 115(6):1131-6.
    View in: PubMed
    Score: 0.061
  13. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci. 2008 Jun; 99(6):1265-73.
    View in: PubMed
    Score: 0.055
  14. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res. 2008 Feb 01; 14(3):788-96.
    View in: PubMed
    Score: 0.054
  15. Imatinib effect on growth and signal transduction in polycythemia vera. Exp Hematol. 2007 Jun; 35(6):931-8.
    View in: PubMed
    Score: 0.051
  16. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. Leuk Res. 2018 04; 67:67-74.
    View in: PubMed
    Score: 0.027
  17. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015 Aug; 1(5):643-51.
    View in: PubMed
    Score: 0.023
  18. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015 Aug 06; 126(6):790-7.
    View in: PubMed
    Score: 0.022
  19. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013 Oct; 123(10):4144-57.
    View in: PubMed
    Score: 0.020
  20. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012 Aug 09; 120(6):1202-9.
    View in: PubMed
    Score: 0.018
  21. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17; 119(20):4614-8.
    View in: PubMed
    Score: 0.018
  22. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009 Nov 10; 27(32):5418-24.
    View in: PubMed
    Score: 0.015
  23. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009 Oct 01; 27(28):4760-6.
    View in: PubMed
    Score: 0.015
  24. Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. Int J Hematol. 2009 Jul; 90(1):58-63.
    View in: PubMed
    Score: 0.015
  25. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008 Sep 01; 112(5):1628-37.
    View in: PubMed
    Score: 0.014
  26. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour. Br J Haematol. 2006 Aug; 134(3):341-3.
    View in: PubMed
    Score: 0.012
  27. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006 Sep 01; 108(5):1497-503.
    View in: PubMed
    Score: 0.012
  28. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006 Aug 15; 108(4):1158-64.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.